Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.61 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.61 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.61 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26956113 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL10499068 | 0.87 | KMT2A (0.64) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL10452171 | 0.87 | KMT2A (0.64) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL8259994 | 0.87 | KMT2A (0.53) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL6380843 | 0.85 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL4027064 | 0.84 | SMN1; SMN2 (0.87) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL6375210 | 0.84 | KMT2A (0.81) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL6376361 | 0.83 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL6377560 | 0.83 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT | |
| SCHEMBL6376395 | 0.83 | MTNR1A (0.71) | SMN1; SMN2ALDH1A1KMT2AMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100393703-C | 1,2,3,4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-11 | — | — | CN | disclosed |
| EP-1274687-B1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-6703392-B2 | OREXIN RECEPTOR ANTAGONISTS FOR OBESITY OR SLEEPING DISORDER TREATMENT | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2003-09-18 | — | — | US | disclosed |
| CN-1416420-A | 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2003-05-07 | — | — | CN | disclosed |
| EP-1274687-A1 | 1,2,3,4- TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001068609-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176415-A1 | 1,2,3,4-tetrahydroisoquinoline derivatives | HCRTR2, HCRTR1, NPY2R | SMN1; SMN2 3406/4885ALDH1A1 1115/4885KMT2A 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.